randomized 1
phase 2
ii 2
trial 1
comparing 1
obinutuzumab 1
ga 1
rituximab 1
patients 2
relapsed 1
cd 1
indolent 2
bcell 1
nonhodgkin 1
lymphoma 2
final 1
analysis 1
gauss 1
study 2
bendamustine 1
rituximabrefractory 1
transformed 1
nonhodgkins 1
results 1
multicenter 1
singleagent 1
